Loading asset research
+0.33%
Today
Loading 1D prices…
Company profile
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
49
Fiscal year end
1231
CIK
1010086
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SLGLSol-Gel Technologies Ltd. Ordinary Shares | $215.9M | $19.4M | -31.60% | -$2.19 | -1.27% | Buy |
| KROSKeros Therapeutics Inc. Common Stock | $219.7M | $244.1M | +35.65% | $2.30 | -0.81% | Buy |
| ELDNEledon Pharmaceuticals Inc. Common Stock | $225.9M | $0.00 | — | -$0.52 | -0.36% | Buy |
| GLSIGreenwich LifeSciences Inc. Common Stock | $226.8M | $0.00 | — | -$1.43 | +2.26% | Buy |
| CUECue Biopharma Inc. Common Stock | $208.8M | $27.5M | -96.85% | -$0.28 | +2.64% | Buy |